SAN ANTONIO, Oct. 22, 2024 – Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is ...
In a major breakthrough for glioblastoma treatment, BioLineRx has announced significant progress on its highly innovative ...
3d
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a ...
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is responsible for providing instructions ...
Scientists have now discovered why a mutation in a gene called TET2 is often implicated in disorders including diabetes, heart disease, stroke, inflammatory diseases, and certain types of cancer. This ...
Inside every cell, inside every nucleus, your continued existence depends on an incredibly complicated dance. Proteins are constantly wrapping and unwrapping DNA, and even minor missteps can lead to ...
IRVING, Texas, Oct. 29, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced collaborative ...
A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset Alzheimer's disease. A team led by researchers at Baylor College of Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results